Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30686120 | 1.00 | FABP5 (0.45) | FABP5FABP7KMT2AAGTR2CD274 | |
| SCHEMBL26763340 | 1.00 | FABP5 (0.45) | FABP5FABP7KMT2AAGTR2CD274 | |
| SCHEMBL30792913 | 1.00 | FABP5 (0.45) | FABP5FABP7KMT2AAGTR2CD274 | |
| SCHEMBL30792870 | 1.00 | FABP5 (0.45) | FABP5FABP7KMT2AAGTR2CD274 | |
| SCHEMBL27028777 | 1.00 | FABP5 (0.45) | FABP5FABP7KMT2AAGTR2CD274 | |
| SCHEMBL30861832 | 0.89 | AGTR2 (0.42) | FABP5FABP7KMT2AAGTR2EPHX2 | |
| SCHEMBL27222159 | 0.89 | AGTR2 (0.42) | FABP5FABP7KMT2AAGTR2EPHX2 | |
| SCHEMBL15083500 | 0.89 | AGTR2 (0.42) | FABP5FABP7KMT2AAGTR2EPHX2 | |
| SCHEMBL29540218 | 0.89 | AGTR2 (0.42) | FABP5FABP7KMT2AAGTR2EPHX2 | |
| SCHEMBL30896059 | 0.88 | FABP5 (0.41) | FABP5FABP7KMT2AAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676702-B2 | Methods for synthesizing amatoxin building block and amatoxins | HEIDELBERG PHARMA GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676702-B2 | Methods for synthesizing amatoxin building block and amatoxins | HEIDELBERG PHARMA GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9630907-B2 | — | — | 2017-04-25 | — | — | US | disclosed |
| US-9630907-B2 | — | — | 2017-04-25 | — | — | US | disclosed |
| US-20150210628-A1 | METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS | HEIDELBERG PHARMA GMBH (DE) | 2015-07-30 | — | — | US | disclosed |
| US-8691848-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2261234-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261235-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261232-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261233-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| EP-2011800-A2 | Inhibitors of caspase | Vertex Pharmaceuticals Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| US-20030232986-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| US-6531474-B1 | Treating inflammatory disease, osteoarthritis, glomerulonephritis, rheumatoid arthritis, psoriasis, graft vs. host disease, sepsis, or septic shock | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-11 | — | — | US | disclosed |
| EP-1064298-A2 | INHIBITORS OF CASPASES | Vertex Pharmaceuticals Incorporated (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047545-A2 | INHIBITORS OF CASPASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048226-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | FABP5 1614/4885FABP7 3485/4885KMT2A 4561/4885 |
| US-20150210628-A1 | METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS | MEP1B, VIP, NMBR | FABP5 1630/4885FABP7 1461/4885KMT2A 2649/4885 |
| US-20030232986-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | FABP5 1852/4885FABP7 3462/4885KMT2A 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.